Related references
Note: Only part of the references are listed.Should non-steroidal anti-inflammatory drugs be used continuously in ankylosing spondylitis?
Dewi Guellec et al.
JOINT BONE SPINE (2014)
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial
Dominique Baeten et al.
LANCET (2013)
Association of TNF-α polymorphism with prediction of response to TNF blockers in spondyloarthritis and inflammatory bowel disease: a meta-analysis
Qiang Tong et al.
PHARMACOGENOMICS (2013)
Treatment Patterns in the First Year After Initiating Tumor Necrosis Factor Blockers in Real-World Settings
Machaon Bonafede et al.
ADVANCES IN THERAPY (2012)
TNF-α-857 and-1031 polymorphisms predict good therapeutic response to TNF-α blockers in Chinese Han patients with ankylosing spondylitis
Qiang Tong et al.
PHARMACOGENOMICS (2012)
Clinical Efficacy and Safety of Etanercept Versus Sulfasalazine in Patients With Ankylosing Spondylitis A Randomized, Double-Blind Trial
Juergen Braun et al.
ARTHRITIS AND RHEUMATISM (2011)
Work Disability in Patients with Ankylosing Spondylitis in Norway
Gunnstein Bakland et al.
JOURNAL OF RHEUMATOLOGY (2011)
Adverse events during biological therapy – focusing on dermatological side-effects
Gabriella Nagy et al.
ORVOSI HETILAP (2011)
Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions
A. Vultaggio et al.
ALLERGY (2010)
Neurological adverse events associated with anti-tumor necrosis factor alpha treatment
Antonio G. Tristano
JOURNAL OF NEUROLOGY (2010)
Immediate complications of 3,555 injections of anti-TNFα
Julio Cesar Bertacini de Moraes et al.
REVISTA BRASILEIRA DE REUMATOLOGIA (2010)
Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis
T. R. D. J. Radstake et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital
Parawee Suwannalai et al.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2009)
Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study
Damien Fouache et al.
RHEUMATOLOGY (2009)
Focus on adverse events of tumour necrosis factor α blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients
V. Gerloni et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
C-reactive protein at the interface between innate immunity and inflammation
Andres Peisajovich et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2008)
Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-α antagonists
H-H. Lee et al.
BRITISH JOURNAL OF DERMATOLOGY (2007)
Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy - Results from the British Society for Rheumatology Biologics Register
W. G. Dixon et al.
ARTHRITIS AND RHEUMATISM (2006)
Predictors of infusion reactions during infliximab treatment in patients with arthritis
Meliha C. Kapetanovic et al.
ARTHRITIS RESEARCH & THERAPY (2006)
Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus
AI Russell et al.
HUMAN MOLECULAR GENETICS (2004)
Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?
D Baeten et al.
ANNALS OF THE RHEUMATIC DISEASES (2003)
Share Paper
